Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.

Wipfler, P; Oppermann, K; Pilz, G; Afazel, S; Haschke-Becher, E; Harrer, A; Huemer, M; Kunz, A; Golaszewski, S; Staffen, W; Ladurner, G; Kraus, J

Wipfler, P; Oppermann, K; Pilz, G; Afazel, S; Haschke-Becher, E; Harrer, A; Huemer, M; Kunz, A; Golaszewski, S; Staffen, W; Ladurner, G; Kraus, J.

Affiliation

Wipfler P; Paracelsus Medical University, Christian-Doppler-Klinik, University Hospital of Neurology, Salzburg, Austria. p.wipfler@salk.at

Mult Scler ; 17(1): 16-23, 2011 Jan.

Article in En | MEDLINE | ID: mdl-20937631

Subject(s)

Antibodies, Monoclonal/administration & dosage; Cell Adhesion Molecules/blood; Immunologic Factors/administration & dosage; Leukocytes, Mononuclear/drug effects; Multiple Sclerosis, Relapsing-Remitting/drug therapy; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antigens, CD/blood; Austria; Biomarkers/blood; Child; Female; Flow Cytometry; Humans; Integrin alpha4/blood; Intercellular Adhesion Molecule-1/blood; Leukocytes, Mononuclear/immunology; Lymphocyte Function-Associated Antigen-1/blood; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting/blood; Multiple Sclerosis, Relapsing-Remitting/immunology; Natalizumab; Prospective Studies; Time Factors; Treatment Outcome; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukocytes, Mononuclear / Cell Adhesion Molecules / Multiple Sclerosis, Relapsing-Remitting / Immunologic Factors / Antibodies, Monoclonal Type of study: Observational_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Mult Scler Year: 2011 Document type: Article

Fulltext

XML

PubMed Links

Search on Google